Showing results (181-190 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|August 21, 2020
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trialsAndrew X Zhu, Ryan D Nipp, Richard S Finn, et al.
ESMO Open|August 21, 2020
Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitorsKartik Anand, Geetanjali Sahu, Ethan Burns, et al.
ESMO Open|August 21, 2020
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancerByung Woog Kang, Ian Chau
ESMO Open|August 22, 2020
erbB in NSCLC as a molecular target: current evidences and future directionsMarzia Del Re, Federico Cucchiara, Iacopo Petrini, et al.
ESMO Open|April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringB Gyawali, E G E de Vries, U Dafni, et al.
ESMO Open|April 8, 2023
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countriesH C Post, T Schutte, M G H van Oijen, et al.
ESMO Open|April 10, 2021
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancerF Schettini, P Barbao, F Brasó-Maristany, et al.
ESMO Open|December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapyM Kerioui, S Desmée, F Mercier, et al.
ESMO Open|November 3, 2022
CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trialM P Saunders, J Graham, D Cunningham, et al.
ESMO Open|November 21, 2023
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort studyJ Colard-Thomas, C Manceron, C Duflos, et al.
Pageof 184